Know Cancer

forgot password

An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer

Phase 2
18 Years
Not Enrolling
Neoplasms, Endometrial, Endometrial Cancer

Thank you

Trial Information

An Open-label, Phase II, Multicenter Study of Intravenous Weekly Topotecan in Subjects With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria:

- A subject will be eligible for inclusion in this study only if all of the following
criteria are met:

- Subject has provided a written informed consent.

- Subject must be female and ≥18 years of age.

- Subjects' original endometrial carcinoma (any histologic type) must have had
pathologic confirmation.

- Subject must have recurrent or persistent endometrial cancer.

- Subject must have at least one measurable lesion according to GOG-modified RECIST

- Measurable disease must be accurately measured in at least one dimension
(longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by
conventional techniques, including palpation, plain X-ray, CT and MRI, or ≥10 mm
when measured by spiral CT.

- Measurable disease found on chest X-ray must be confirmed with CT or MRI. Either
CT or MRI must be used throughout the study to further evaluate these lesions.

- The same diagnostic method (CT, MRI, X-ray or physical exam) used to evaluate
disease, must be used throughout the study to consistently evaluate lesions.

- Palpable tumor masses that cannot be evaluated by CT or MRI scan should be
evaluated by ultrasound or confirmed by biopsy.

- Evaluable disease (measurable or non-measurable) may be in a field of prior
radiation provided that at least six weeks have elapsed since receiving
radiation and disease progression is clearly documented by radiographic study.
It is preferential for the target lesion to be located outside an irradiated

- Non-measurable disease is defined as all other lesions, including small lesions
(longest diameter <20 mm with conventional techniques or <10 mm with spiral CT

- Subject has received one prior chemotherapy regimen (excluding all topoisomerase I
inhibitors e.g., HYCAMTIN and irinotecan).

- Subject is allowed to have received, but is not required to have received, one
additional prior non-cytotoxic regimen for management of recurrent or persistent
disease according to the following definition: Non-cytotoxic (biologic or cytostatic)
agents include, but are not limited to, monoclonal antibodies, cytokines, and small
molecule inhibitors of signal transduction. UM2004/00031/00 CONFIDENTIAL HCT100414 20

- Subject is at least 21 days from prior chemotherapy and at least 30 days from prior
non-cytotoxic therapy and is recovered from associated toxicities.

- Subject must not have received radiotherapy for at least seven days.

- Subject must be at least three weeks since last major surgery (a lesser period is
acceptable if deemed in the best interest of the subject). Subject must have an ECOG
Performance Status of 0 or 1 (refer to

- Appendix 4, ECOG Performance Status).

- Subject must have, at screening, a probable life expectancy of at least three months.

- Subject of childbearing potential must be practicing adequate contraception [e.g.,
oral contraceptives, diaphragm plus spermicide, or intrauterine device (IUD)] or show
documented complete abstinence from intercourse for at least three months prior to
study start. The same contraceptive method should be used throughout the study and
continue for at least four weeks after the end of the study. A subject will be
considered of childbearing potential if not surgically sterile or post-menopausal
(i.e., documented absence of menses for one year prior to entry into the study).

14. Subject must have screening laboratory criteria as follows:

- Hemoglobin ≥ 9.0 g/dL.

- Neutrophils ≥ 1,500/mm³ [≥1.5 x 10^9/L].

- Platelets ≥ 100,000/mm³ [≥100.0 x 10^9/L].

- Creatinine ≤ upper limit of normal (ULN) or creatinine clearance (Clcreat) ≥

- Creatinine clearance should be calculated using the Cockcroft-Gault formula:

Clcreat (mL/min) = (140-age [yr] x body wt [kg] x 0.85 72 x serum creatinine [mg/dL] OR
Clcreat (mL/min) = 1.05 x (140-age [yr] x body wt [kg] serum creatinine [μmol/L]

- Serum bilirubin within normal limits.

- Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline
phosphatase < 2xULN if liver metastases are absent by abdominal CT or MRI or < 5xULN
if liver metastases are present.

Exclusion Criteria:

A subject will not be eligible for inclusion in this study if any of the following
criteria are met:

- Subject is pregnant or lactating.

- Subject has received more than one prior chemotherapy regimen. UM2004/00031/00

- Subject has concomitant or history of previous malignancies, with the exception of
adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer,
or other cancer from which the subject has been disease-free for five years.

- Subject has active uncontrolled infection.

- Subject has brain metastases as documented by CT or MRI. Note: Asymptomatic subjects
do not require CT or MRI to rule out brain metastases.

- Subject has received prior treatment with HYCAMTIN.

- Subject has a history of an allergic reaction to compounds chemically-related to
HYCAMTIN or its constituents.

- Subject has received any investigational agent within 30 days or five half-lives
(whichever is longer) prior to study entry.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Best Overall Response

Outcome Description:

Tumor response based on GOG (Gynecological Oncology Group) modified RECIST (Response Evaluation Criteria In Solid Tumors) criteria. A 4-point scale used specifying tumor response. Complete Response (CR): Disappearance of all target lesions; Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions; (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; (PD): At least a 20% increase in the sum of the LD of target lesions

Outcome Time Frame:

Week 0 to Week 98 when endpoints were met

Safety Issue:


Principal Investigator

GSK Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:



Hungary: National Institute of Pharmacy

Study ID:




Start Date:

October 2005

Completion Date:

December 2007

Related Keywords:

  • Neoplasms, Endometrial
  • Endometrial Cancer
  • Hycamtin
  • endometrial cancer
  • topotecan
  • Neoplasms
  • Endometrial Neoplasms
  • Sarcoma, Endometrial Stromal
  • Adenoma



GSK Investigational Site Bakersfield, California  93309
GSK Investigational Site Gainesville, Florida  32610
GSK Investigational Site New Orleans, Louisiana  70112
GSK Investigational Site Duluth, Minnesota  55805
GSK Investigational Site Savannah, Georgia  31405
GSK Investigational Site Park Ridge, Illinois  60068
GSK Investigational Site Columbia, South Carolina  29210
GSK Investigational Site Germantown, Tennessee  38138
GSK Investigational Site Aurora, Colorado  80012
GSK Investigational Site Omaha, Nebraska  68131
GSK Investigational Site Seattle, Washington  98133